Regulatory Pathways FDA and EMA – Are You Prepared for Ongoing AI Supervision?
Regulatory pathways in the United States and Europe are becoming more complex. The FDA and the EMA continue to raise expectations for data quality, transparency, and oversight. At the same time, regulators are expanding their use of advanced digital tools, including artificial intelligence, to review submissions, monitor compliance, and identify risk.
The Power of AI
Large language models (LLMs), like Gemini from Google, are emerging as powerful tools, streamlining the document creation process and allowing human expertise to shine even brighter.